Holen Sie sich die Stockscreener-App
5.94
1.98%
-0.12
Handel nachbörslich:
5.94
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue Stage - Newser
Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale - Investing.com
GYRE (GYRE) COO sells 22,220 shares after stock option exercises - Stock Titan
GYRE Stock Price, Quote & Chart | GYRE THERAPEUTICS INC (NASDAQ:GYRE) - ChartMill
Gyre Therapeutics (GYRE) director cancels 250,000-share stock option agreement - Stock Titan
Gyre Therapeutics COO Ye Weiguo sells $59,418 in shares - Investing.com
Gyre Therapeutics (GYRE) COO sells shares after exercising options - Stock Titan
Gyre Therapeutics (GYRE) Stock: Slides -2.17%, Support at $5.98 2026-05-19Advance Decline Volume - Newser
GYRE (GYRE) COO Ye exercises options and sells 28,680 shares in May - Stock Titan
Gyre Therapeutics (GYRE) Fell -6.43% — Is a Recovery Ahead? 2026-05-17Community Momentum Stocks - Newser
Gyre Therapeutics and Cullgen Advance CDK2-Cyclin E Degrader CG923308 for Treatment of Solid Tumors and CDK4/6i-Resistant Breast Cancer - Minichart
GYRE Should I Buy - Intellectia AI
Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion - TipRanks
Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027 - TradingView
Gyre Therapeutics (NASDAQ: GYRE) showcases degrader pipeline and CG923308 IND plans - Stock Titan
Gyre Therapeutics stock (KYG4200L1031): Low short interest signals stability amid pharma peers - AD HOC NEWS
China regulator accepts Gyre’s liver fibrosis drug application By Investing.com - Investing.com India
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (Hydronidone) to Treat CHB-Induced Liver Fibrosis - Minichart
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment - The Manila Times
Gyre Therapeutics’ F351 NDA Accepted for Priority Review - TipRanks
Gyre Therapeutics announces NMPA acceptance of new drug application for F351 (hydronidone) - marketscreener.com
Gyre Therapeutics (GYRE) wins NMPA review acceptance for F351 liver fibrosis NDA - Stock Titan
GNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition - TipRanks
China regulator accepts Gyre’s liver fibrosis drug application - Investing.com India
New hepatitis B liver drug for China’s tens of millions enters NMPA review - Stock Titan
TradingKey - TradingKey
Number of shareholders of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
[144] GYRE THERAPEUTICS, INC. SEC Filing - Stock Titan
Q2 EPS Forecast for Gyre Therapeutics Reduced by Analyst - MarketBeat
Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics, Inc. 10-Q Quarterly Financial Report March 31, 2026 – Financial Statements, Risk Factors, and Disclosures - Minichart
Gyre Therapeutics (NASDAQ: GYRE) Q1 2026 results and $300M Cullgen deal - Stock Titan
Gyre Therapeutics stock (KY.G4200L1031): Acquisition of Cullgen and Q1 2026 results in focus - AD HOC NEWS
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Ramps Up F351 and Cullgen Investments as Q1 Swings to Loss - TipRanks
Gyre Therapeutics CEO Luo Ying sells $82,927 in company stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics CEO Luo Ying sells $82,927 in company stock - Investing.com India
Gyre Therapeutics (GYRE) CEO spouse sells 10,315 shares under plan - Stock Titan
Gyre Therapeutics (GYRE) CSO discloses new Series B stake - Stock Titan
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
GYRE STOCK ALERT: Kaskela Law Firm Announces Shareholder Investigation into Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm - ACCESS Newswire
Gyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) reports Q1 loss, lags revenue estimates - MSN
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (GYRE) Gyre Therapeutics, Inc. Reports Q1 Revenue $22.5M, vs. FactSet Est of $31.6M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q1 Loss $0.10 a Share, vs. FactSet Est of $0.07 Loss - marketscreener.com
Q1 2026 loss and Cullgen deal reshape Gyre Therapeutics (NASDAQ: GYRE) - Stock Titan
Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates - TradingView
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update - The Manila Times
Gyre pairs China drug filing with $300M Cullgen deal after Q1 - Stock Titan
Gyre Therapeutics (GYRE) holders update 6.33% stake after $300M Cullgen all‑stock merger - Stock Titan
Cullgen deal gives Gyre Therapeutics (GYRE) holders new preferred and lock-up terms - Stock Titan
GNI Group’s Gyre Therapeutics Completes US$300 Million Cullgen Acquisition to Build Integrated U.S.-China Biopharma Platform - TipRanks
GNI group takes 69.1% Gyre (NASDAQ: GYRE) stake after $300M Cullgen deal - Stock Titan
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):